Wells Fargo Downgrades Regeneron Pharmaceuticals (WBAG:REGN)

Wells Fargo downgraded Regeneron Pharmaceuticals (REGN) from Overweight to Equal-Weight on May 30, 2025, while the average analyst one-year price target suggests a 69.77% upside. Despite this potential upside, fund sentiment has decreased, with the number of institutions holding REGN declining by 3.30% in the last quarter and several major holders, including Jpmorgan Chase and Capital International Investors, reducing their positions.

Analysis

Wells Fargo revised its outlook for Regeneron Pharmaceuticals (WBAG:REGN) to Equal-Weight from Overweight on May 30, 2025, signaling a more cautious stance on the stock. This downgrade contrasts with the average one-year analyst price target of €730.67 as of May 7, 2025, which implies a substantial 69.77% potential upside from Regeneron's latest reported closing price of €430.40 per share. However, institutional sentiment appears to be weakening, evidenced by a 3.30% decrease in the number of funds reporting positions and a 0.93% reduction in total shares owned by institutions to 113,247K in the last quarter. Notably, Jpmorgan Chase significantly reduced its holdings by 24.76% and its portfolio allocation in REGN by a drastic 92.61%, while Capital International Investors decreased its shareholding by 18.75% and its allocation by 21.50%. While some large index funds such as Vanguard's VTSMX and VFINX reported marginal increases in shares held (0.26% and 2.51% respectively), they concurrently decreased their portfolio allocations to REGN, suggesting these share increases are likely attributable to passive fund flows or rebalancing rather than active bullish conviction. The company's projected annual revenue growth is modest at 0.79%, reaching 14,197MM, with a projected annual non-GAAP EPS of 46.69, potentially contributing to the cautious institutional behavior despite optimistic analyst price targets.

Key Decisions for Investors

• Investors should critically evaluate the divergence between Wells Fargo's downgrade and significant institutional selling, particularly the substantial position reductions by active managers like Jpmorgan Chase, against the high consensus analyst price target upside.
• The projected modest annual revenue growth of 0.79% for Regeneron Pharmaceuticals warrants close scrutiny, as this figure may be a key factor influencing the tempered institutional outlook and the recent analyst downgrade.
• Consider a cautious approach, monitoring upcoming earnings, further analyst commentary, and any fundamental developments that could clarify the conflicting signals between optimistic price targets and the observed institutional selling pressure before adjusting positions.